- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus
PALO ALTO, Calif., June 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom. Title: Lonafarnib Combination with Peginterferon Lambda Diminished Triphasic HDV Kinetic Pattern Authors: Duehren, S.; Heller, T. et al.
Session: Hepatitis B Emerging Therapies
Date & Time: June 25, 8:30 a.m. - 8:45 a.m. British Summer Time (BST)
Title: Strong Correlation Between HBsAg, ALT and HDV-RNA Levels in Patients with Chronic Hepatitis Delta: Results of Phase 3 D-LIVR Study
Authors: Buti, M.; Lampertico, P. et al.
Date & Time: June 23, 9:00 a.m. - 6:30 p.m. BST
Authors: Etzion, O.; Lampertico, P. et al.
Date & Time: June 23, 9:00 a.m. - 6:30 p.m. BST
Title: Mathematical Modeling of HDV RNA Kinetics Suggests High Peginterferon Lambda Efficacies in Blocking Viral Production and Infection: Insights from the LIMT-1 Study Authors: Cardozo-Ojeda,, E.F.; Etzion, O. et al
Date & Time: June 25, 9:00 a.m. - 6:00 p.m. BST
Event: 21st Hepatitis Delta International Network
Date & Time: June 22, 4:00 p.m. BST
Location: ExCel London, South Gallery 27
Presenter: Ingrid Choong, Ph.D., SVP, Clinical Development Eiger BioPharmaceuticals
Date & Time: June 23-25, 9:00 a.m. - 5:00 p.m. BST
Event: Eiger Reception for Investigators, Investors and Analysts Date: June 23, 5:30 - 7:00 p.m. BST
Location: Prince Regent #3
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from TOGETHER, a Phase 3 investigator-initiated study. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. Wheelhouse Life Science Advisors